Revenue
2020
2021
2022
2023
2024
2025
Rapid Micro Biosystems, Inc. (RPID)
Price$1.31Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $33.6M | $28.1M | $22.5M | $17.1M | $23.2M | $16.1M |
| Research & development | $13.6M | $14.6M | $12.8M | $12.9M | $9.8M | $6.5M |
| Operating expenses | $81.0M | $78.0M | $79.1M | $80.4M | $70.5M | $46.6M |
| Operating income | −$47.4M | −$49.9M | −$56.6M | −$63.2M | −$47.2M | −$30.5M |
| Operating margin | −141.10% | −177.96% | −251.18% | −368.99% | −203.31% | −189.96% |
| EBITDA | −$44.1M | −$46.6M | −$53.5M | −$60.4M | −$45.7M | −$29.0M |
| EBITDA margin | −131.42% | −165.97% | −237.39% | −352.43% | −196.72% | −180.57% |
| Net income | −$47.1M | −$46.9M | −$52.5M | −$60.8M | −$73.5M | −$37.1M |
| Net profit margin | −140.30% | −167.16% | −232.99% | −354.91% | −316.48% | −230.63% |
| Basic EPSper basic share | -$1.05 | -$1.08 | -$1.22 | -$1.43 | -$3.94 | -$126.11 |
| Diluted EPSper diluted share | -$1.05 | -$1.08 | -$1.22 | -$1.43 | -$3.94 | -$126.11 |
Owners
Reported shareholders
18.55%of listed shares
Bain Capital Life Sciences Investors, LLC8.43M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Bain Capital Life Sciences Investors, LLC | 18.55%8.43M shares |
Longitude Venture Partners II, L.P. / ENRIGHT PATRICK G / Tammenoms Bakker Juliet / Longitude Prime Fund, L.P. / Longitude Prime Partners, LLC / Longitude Capital Partners II, LLC | ≈8.86%4.03M shares |
ARMISTICE CAPITAL, LLC | 7.32%3.33M shares |
ABG-WTT Global Life Science Capital Partners GP Ltd | 4.07%1.85M shares |
Spignesi Robert G. Jr. | ≈2.62%1.19M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.16%982.03K shares |
WIRTJES SEAN M | ≈1.25%568.98K shares |
Evernest Financial Advisors, LLC | 1.11%506K shares |
Advent International, L.P. | 0.84%379.79K shares |
ESSEX INVESTMENT MANAGEMENT CO LLC | 0.80%362.7K shares |
Wilson John J. Addington | ≈0.70%316.76K shares |
MILLENNIUM MANAGEMENT LLC | 0.52%236.6K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.50%228.04K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.47%212.1K shares |
BlackRock, Inc. | 0.42%189.83K shares |
Kollender Richard S | ≈0.29%130.32K shares |
Legato Capital Management LLC | 0.26%119.53K shares |
VANGUARD FIDUCIARY TRUST CO | 0.24%110.48K shares |
DIMENSIONAL FUND ADVISORS LP | 0.23%104.19K shares |
PEI MELINDA LITHERLAND | ≈0.22%100.69K shares |
Percentages use 45.47M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 20, 2026Form 4 | Bain Capital Life Sciences Fund, L.P. +3TenPercentOwner | BuySeries B Warrant (right to buy) · derivative · indirect | 1.46M | — | — | 1.46M |
| May 20, 2026Form 4 | Bain Capital Life Sciences Fund, L.P. +3TenPercentOwner | BuySeries A Warrant (right to buy) · derivative · indirect | 1.46M | — | — | 1.46M |
| May 20, 2026Form 4 | Bain Capital Life Sciences Fund, L.P. +3TenPercentOwner | BuyPre-Funded Warrant (right to buy) · derivative · indirect | 1.46M | — | — | 1.46M |
| Mar 11, 2026Form 4 | Wilson John J. AddingtonCHIEF OPERATING OFFICER | SellClass A Common Stock | 9.6K | $4.32 | $41.5K | 316.8K |
| Mar 11, 2026Form 4 | WIRTJES SEAN MCHIEF FINANCIAL OFFICER | SellClass A Common Stock | 7.5K | $4.32 | $32.3K | 556.2K |